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Novel 9-(substituted amino/piperazinoethyl)adenines (4e12), 6-(substituted piperazino/amino)purines
(15e27), 9-(p-toluenesulfonyl/cyclopentyl/ethoxycarbonylmethyl)-6-(substituted amino/piperazino)pu-
rines (28e34, 36, 37, 38e41) were synthesized and evaluated initially for their cytotoxic activities on liver
Huh7, breast T47D and colon HCT116 carcinoma cells. N6-(4-Trifluoromethylphenyl)piperazine derivative
(17) and its 9-(p-toluene-sulfonyl)/9-cyclopentyl analogues (28, 36) had promising cytotoxic activities.
Compounds 17, 28 and 36 were further analysed for their cytotoxicity in a panel of a liver cancer cell
lines. The compound 36 had better cytotoxic activities (IC50  1 mM) than the nucleobase 5-FU and
nucleosides fludarabine, cladribine, and pentostatine on Huh7 cells. Cytotoxicity induced by 36 was later
identified as senescence associated cell death by SA-b-Gal assay.
© 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
Nucleobase analogues, which are structurally, metabolically and
pharmacodynamically similar, are known to have different bio-
logical activities [1]. These diverse effects have been reported to be
associated with anti-cancer, anti-viral, anti-fungal and anti-
bacterial activities due inhibition of the enzymes involved in cell
proliferation [2e24]. The nucleobase analogues induce apoptosis
during growth and division, which is a common inhibitory mech-
anism observed in the presence of these molecules [25]. A well-
known pioneer fluorinated nucleobase analogue, 5-fluorouracil, is
highly preferred in clinics for the treatment of various cancers [26].
Later, other pyrimidine analogues such as arabinofuranosyl cyti-
dine (Ara-C) and gemcitabine have been identified as antimetab-
olite chemotherapeutic agents in cancer [1]. Purine derivatives, 6-
mercaptopurine and 6-thioguanine have been used as an inhibi-
tor of nucleic acid metabolism in paediatric acute lymphoblastic
leukaemia [27]. Furthermore purine nucleoside analogues such asAtalay), tuncbile@pharmacy.
served.fludarabine, cladribine, and pentostatine, emerged as a group of
antimetabolites against haematological malignancies in clinics
[28].
Nucleoside analogues interfere with the integrity of DNA by
impairing dNTP pools and ultimately DNA synthesis through ribo-
nucleotide reductase (RR) inhibition [29]. Due to the altered DNA
integrity, which is detected as damaged by cellular machinery, the
treatment with nucleoside analogues induces apoptosis [1]. There
are also nucleoside analogues such as toyocamycin and decitabine,
which have been reported to induce senescence, associated cell
death [30,31]. Recently senescence-associated cell death, which is a
cellular event in tumour development and progression as well as
treatment, was reported as premature senescence in cancer cells
[32]. Therefore, senescence induced cell death through pro-
senescence therapy is currently the target of small molecule in-
hibitors [33,34].
Primary liver cancer, hepatocellular carcinoma (HCC), is the
sixth most common and the third lethal cancer [35]. Sorafenib, a
kinase inhibitor, is the only FDA approved drug for HCC treatment
and extends the mean survival of the patients only for 3 months
[36]. Thus, it is essential to discover new chemotherapeutic agents
for the treatment of this cancer. Here, we synthesized a series of 9-
substituted adenines (4e12), 6-substituted purines (15e27) and
Z. Demir et al. / European Journal of Medicinal Chemistry 89 (2015) 701e7207026,9-disubstituted purine analogues (28e34, 36e41) and evaluated
their cytotoxic activities against liver (Huh7), colon (HCT116), and
breast (T47D) carcinoma cell lines; and the most active purine
analogues (17, 28, and 36) were further tested on a panel of liver
cancer cells. Moreover, we further characterized the most bioactive
compound 36 an agent inducing senescence associated cell death
with a remarkable cytotoxicity (IC50  1 mM).
2. Result and discussion
2.1. Chemistry
The synthesis of the 9-(substituted amino/piperazinoethyl)
adenine derivatives 4e12 was carried out starting from commer-
cially available adenine (1) (Scheme 1). The base catalysed nucle-
ophilic addition of 1 to ethylene carbonate afforded 9-(2-
hydroxyethyl)-9H-adenine (2) [37]. The nucleophilic addition re-
action occurred only at the N-9 atom. The hydroxyethyl compound
(2) was chlorinated with SOCl2 to give intermediate 9-(2-
chloroethyl)-9H-adenine (3) [37]. Compounds 4e12 were synthe-
sized by nucleophilic substitution of chlorine of (3) with the
appropriate amine and piperazines.
6-Chloro-9-p-toluensulfonyl-9H-purine (14) was prepared from
6-chloropurine and p-toluensulfonyl chloride under Schotten-
Baumann conditions [38]. The amination of 14 with 1-(2-
hydroxyethyl)piperazine did not afford the desired product and
compound 15 was formed (Scheme 2). This reaction sequence wasScheme 1. Reagents: i) Ethylene carbonate, NaOH, DMF; ii) SOCl2; iii) tnot applicable for the synthesis of 6,9-disubstituted purine de-
rivatives 28e34. Thus, 9-(p-toluene-sulfonyl)-6-substituted amino/
piperazinopurines (28e34) were first synthesized as shown in
Scheme 3. Purines substituted at C-6 (15e27) were synthesized by
nucleophilic substitution of the chlorine of 6-chloropurine (13)
with the appropriate amine and piperazines in the presence of
base. Compounds 15e27 were N-sulfonylated with complete
regioselectivity applying the same set of reaction conditions as
reported for the sulfonylation of adenine [39]. The sulfonylation
reaction occurred only at the N-9 atom, without the concurrent N-7
sulfonylation, as proved by the X-ray crystallographic analysis of
the structure of compound 28 (Figs. 1 and 2).
9-Cyclopentyl-substituted purines 36, 37 [24] were synthesized
via N-9 alkylation of 13 with cyclopentyl bromide, and by amina-
tion of 6-chloro-9-cyclopentylpurine 35 with 4-(4-
trifluoromethylphenyl)piperazine or 4-methylpiperidine (Scheme
4). The alkylation reaction occurred only at the N-9 atom. X-ray
analysis [24] also confirmed the structure of compound 35.
Compounds 15, 17, 22, 24 could be alkylated with ethyl chlor-
oacetate in DMF by first generating the anionwith NaH (Scheme 5).
This procedure yielded only one isolable compound which was
identified as the expected 9-acetat substituted purines (38e41). 1H
NMR Nuclear Overhauser Effect Spectroscopy (NOESY) also sup-
ported the structure of N-9 regioisomer 41. The NOE interaction
showed coupling between purine NeCH2 and H-8 protons, but no
such interactions between any of the piperazine and purine NeCH2
protons eliminate N-7 acetylation. On the other hand, thehe appropriate amine, EtOH; iv) the appropriate piperazine, EtOH.
Scheme 2. Reagents: i) p-Toluensulfonyl chloride, KOH, H2O, acetone; ii) 1-(2-hydroxyethyl)piperazine, EtOH.
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ortho protons (Fig. 3).
2.1.1. X-ray crystal structure analysis of compound 28
Solid state packing of the compound 28 was investigated by
using X-ray crystallography. The unit cell of 28 contains two crys-
tallographically independent purine molecules named A and B in
the asymmetric unit as shown in Fig. 1. The molecular structure
with atom numbering scheme and the packing arrangement of the
molecules are presented in Figs. 1 and 2. Details of crystallographic
data and structure refinement parameters are given in Table 1.
The skeleton of the molecule consists of a purine moiety, a p-
toluenesulfonyl moiety connected to N9 atom and the piperazine
substituent (which contains trifluoromethyphenyl group) at C6 of
the purine ring system. The purine moiety is almost planar and the
dihedral angles between the mean planes of the pyrimidine and
imidazole rings are 1.4 (1) and 2.7 (1) for molecule A and B,
respectively. The toluene ring joined to the purine moiety by a
sulfonyl group is planar and forms an angle of 82.6(1) in molecule
A [79.0(1) for B] with the average plane of the purine ring system.
The conformation of the sulfonyl junction is characterized by the
torsion angles C4AeN9AeS1eC10A ¼ 70.2(3) and
N9AeS1eC10AeC15A ¼ 86.8(3) [these values are 70.4(3)  and
e84.5(3)  for molecule B].
In (trifluoromethylphenyl)piperazine part of the compound 28,
the piperazine ring adopts a chair conformation. The perpendicular
distances of the two chair atoms in the 4. position (N1A0 and N4A0)
from the plane of the other four atoms of the six-membered
piperazine ring are 0.585(3) and e0.559(4) Å for molecule A (for
N1B0 and N4B0of molecule B are 0.346(4) ande0.378(4) Å,respectively). The dihedral angle between the best planes of the
purine moiety and piperazine ring is 23.2(2) and 15.4(2) for A and
B molecules. The phenyl ring connected to the piperazine is also
planar andmakes an angle of 23.1(2) for A [16.2 (2) for B] with the
plane defined by the four atoms of the piperazine ring.
In the structure, there is no classical intermolecular hydrogen
bond. The packing diagram shows that the molecules are arranged
in rows running parallel to the c-axis with the molecules in adja-
cent rows inverted.
2.2. Biological evaluation and discussion
The cytotoxicities of the compounds 4e12, 14e34, 36e41 were
initially analysed on liver (Huh7), colon (HCT116) and breast (T47D)
carcinoma cell lines (Table 2). The IC50 values after 72 h of treat-
ment with each molecule were also calculated in comparison with
the nucleobase analogue 5-fluorouracil (5-FU) and nucleoside an-
alogues fludarabine, cladribine, pentostatine. 9-Substituted
adenine derivatives (4e12) did not show any significant cytotoxic
activity. By replacing the C-6 NH2 group (4e12) with a Cl atom (14)
resulted an increase in the cytotoxic activity against Huh7
(20.8 mM), HCT116 (22.8 mM), and T47D (13.9 mM).
Among 6-substituted amino purine analogues, 6-(2-
cyclohexenylethyl)amino-9H-purine (26) and its 9-(p-toluene-sul-
fonyl) derivative (34) had promising IC50 against Huh7 (14.2 mM
and 9.4 mM), HCT116 (12.9 mM and 8.7 mM), and T47D (40.3 mM and
34.5 mM) values upon 72 h of treatment. The substitution of p-
toluene-sulfonyl at N-9 position enhanced the cytotoxic activity of
the compound (34) and the IC50 values for 72 h of treatment were
comparable to the well-known nucleobase analogue 5-FU (Table 2).
Scheme 3. Reagents: i) The appropriate piperazine or 4-methylpiperidine, Et3N, EtOH/nBuOH; ii) p-toluensulfonyl chloride, pyridine, CH2Cl2; iii) the appropriate amine, Et3N, EtOH/
nBuOH.
Fig. 1. Two molecules in the asymmetric unit of 28, showing the atom numbering
scheme; displacement ellipsoids are drawn at the 30% probability level.
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and its 9-cyclopentyl derivative (37) displayed very similar cyto-
toxicitiesas well. Therefore the effect of cyclopentyl substitution at
N-9 position was not very significant (Table 2). Among the com-
pounds synthesized in this study, analogues accommodating
substituted benzyl at their C-6 position (21, 22, 23, 24, 31, 32, 33, 38,
and 39), 6-(2,4-dichlorobenzyl)amino-9-p-toluenesulfonyl-9H-pu-
rine (33) had noteworthy IC50 values against Huh7 (26.9 mM),
HCT116 (28.1 mM), and T47D (47.6 mM) is upon 72 h of treatment.
When we evaluated the group of 9-acetate substituted purines
(38e41), the 4-(4-trifluoromethylphenyl)piperazine substituted at
C-6, the analogue 41, was the only 9-acetate derivative with an
apparent IC50 (Table 2). The data presented in Table 2, indicated that
the 4-(4-trifluoromethylphenyl)piperazine substitution was the
most active group responsible for the cytotoxic activity.
Compounds 17, 28, and 36 have remarkable cytotoxic activities
out of four purine analogues having 4-(4-trifluorophenyl)pipera-
zine. When we compared their IC50 values upon for 72 h of treat-
ment with the known cell growth inhibitors 5-FU, Fludarabine and
Pentostatine, we observed that 17which has no substitution at N-9
Fig. 2. The crystal packing in 28, showing the stacks of molecules running down the c
axis.
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(28, 36) had showed more potent cytotoxicities in micromolar
concentration ranges. Furthermore, 36 had a better cytotoxic ac-
tivity than the known nucleoside drug, cladribine on Huh7 and
HCT116 (0.2, <0.1 vs. 1.8 and 0.3 mM for cladribine, Table 2).
Therefore, these compounds (17, 28, 36) were further analysed
against a hepatocellular carcinoma (HCC) cell line panel consisting
of Huh7, HepG2, Hep3B, PLC, SK-Hep1, Mahlavu, FOCUS, Snu182,
Snu475cells. We observed the most significant cell growthScheme 4. Reagents: i) Cyclopentyl bromide, K2CO3, DMF; ii) 4-(4-triflinhibition in the presence of 9-cyclopentyl derivative, 36, with IC50
values of 0.2e9.6 mM (Table 3, Fig. 4). The 9-(p-toluene-sulfonyl)
analogue 28was also very active IC50 values in range of 1.0e8.4 mM
against all tested cell lines upon 72 h of treatment.
2.2.1. 17, 28 and 36 induces nuclear condensation that is devoid of
apoptosis or necrosis
To further clarify the cytotoxic effect emerged in cancer cells
treated with these three novel purine derivatives, we analysed
these cells under florescence microscopy with Hoechst 33258
staining. After the observation of condensed apoptotic nuclei
bearing horseshoe-like structures, (Fig. 5A) in the presence of 17, 28
and 36, we confirmed apoptosis through inspecting the expression
levels of certain proteins known as apoptosis markers with western
blot analysis. Staurosporine (STS) was used as positive control at its
apoptosis-inducing dose. The poly (ADP-ribose) polymerase (PARP-
1), a 113 kDa nuclear protein, known to be cleaved into fragments of
89 kDa and 24 kDa fragments during apoptosis, was analysed in the
presence of the compounds. Mahlavu cells treated with 17, 28 and
36 at IC50 values for 72 h thenwere analysed for apoptosis by PARP-
1 cleavage assay via western blot. Compared to STS, the apoptotic
fragment, cleaved-PARP (89 kDa) gave a weak signal while the
24 kDa and necrosis dependent fragment 55 kDa fragment were
absent (Fig. 5B). In addition the expression levels of the anti-
apoptotic protein Bcl-2 and total Cytochrome-c levels were not
altered in the presence of novel purine analogues (data not shown).
Hence, the underlying mechanism of the cytotoxic action of these
three purine analogues couldn't be considered as apoptosis or
necrosis.
2.2.2. Compounds 17, 28 and 36 had an effect on the ATP pool of
the cells comparable to their PARP cleavage activity
The growth inhibitory effects that we observed with these three
purine derivatives were comparable to that of 5-fluorouracil
(IC50 ~ 10 mM, for 72 h, Table 2). The differential (cell-line-depen-
dent) cytotoxic activity of each molecule can be considered as an
indicator of the specificity of these inhibitors against their target.
They might interfere with the activity of certain kinases instead of
acting as a multi-kinase inhibitor. Therefore, we evaluated the
protein kinase inhibitory activity of these purine analogues. Theuoromethylphenyl)piperazine or 4-methylpiperidine, Et3N, EtOH.
Scheme 5. Reagents: i) ClCH2COOEt, NaH (95%), DMF.
Fig. 3. Selected NOE interactions in structure of 41.
Table 1
Crystal data and details of the structure determination of 28 compound.
Crystal formula C23H21N6O2F3S
Formula weight 502.52
Crystal dimensions, [mm3] 0.710  0.503  0.310
Temp, [ K] 293(2)
Wavelength, [Å] 0.71073
Crystal system Triclinic








Range of q, [] 1.68 to 26.71
Abs. coefficient, [mm1] 0.20
Absorption correction Integrated
Tmin, Tmax 0.9052, 0.9626
Reflections collected 35,292
Reflections used in refinement 9699
No. of refined parameters 631




(Dr)min, (Dr)max (e Å3) 0.47, 0.39
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reaction mixture through bioluminescence was performed with
Huh7 and Mahlavu cells (Fig. 6) [40,41]. The liver cancer cells
incubated for 24 h with these new cytotoxic molecules and STS, amulti-kinase inhibitor used as a positive control. The decrease in
intrinsic cellular ATP consumption, in other words increase in the
light intensity, in the presence of these three purine analogues was
more apparent in Huh7 cells compared to Mahlavu cells. Interest-
ingly, the comparative cleaved-PARP levels in Mahlavu cells upon
17, 28, 36 and STS treatment was very similar to the comparative
kinase inhibitory potential of these three novel purine analogues
and STS in Mahlavu cells (Figs. 5B and 6). Based on the results we
obtained, the newly synthesized purine derivatives, 17, 28 and 36
can be considered as putative protein kinase inhibitors, whichmust
be further analysed at the molecular level.
N6-(4-Trifluoromethylphenyl)piperazine derivative, compound
36, displayed the greatest cytotoxic activity with IC50 less than 1 mM
Table 2
In vitro cytotoxicity of compounds 4e12, 14e34, 36e41 on different human cancer cell lines.
Compound R R1 Cancer cell line, IC50(mM)a
Huh7 HCT116 T47D
4 NH2 NI NI NI
5 NH2 NI NI NI
6 NH2 NI NI NI
7 NH2 NI NI NI
8 NH2 NI NI NI
9 NH2 NI NI NI
10 NH2 NI NI NI
11 NH2 NI NI NI
12 NH2 NI NI NI
14 Cl 20.8 22.8 13.9
15 H NI NI NI
(continued on next page)
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Table 2 (continued )
Compound R R1 Cancer cell line, IC50(mM)a
Huh7 HCT116 T47D
16 H NI NI NI
17 H 3.2 5.1 39.4
18 H NI NI NI
19 H NI NI NI
20 H NI NI NI
21 H NI 86.6 NI
22 H 68.3 102.1 NI
23 H NI NI NI
24 H NI NI 146.8
25 H NI 131.6 NI
26 H 14.2 12.9 40.3
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Table 2 (continued )
Compound R R1 Cancer cell line, IC50(mM)a
Huh7 HCT116 T47D
27 H NI NI NI
28 1.4 4.5 42.7
29 17.8 14.6 22.5
30 NI NI NI
31 NI NI NI
32 NI NI 116.4
33 26.9 28.1 47.6
34 9.4 8.7 34.5
36 0.2 <0.1 <0.1
(continued on next page)
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Table 2 (continued )
Compound R R1 Cancer cell line, IC50(mM)a
Huh7 HCT116 T47D
37 17.4 16.6 21.0
38 NI >200 NI
39 NI NI 99.9
40 NI NI NI
41 53.3 72.4 NI
5-FU 30.7 6.0 7.9
Fludarabine 60.1 6.6 46.2
Cladribine 1.8 0.3 0.7
Pentostatine NI NI NI
NI: no inhibition.
a IC50 values were calculated from the cell growth inhibition percentages obtained with 5 different concentrations (40, 20, 10, 5, and 2.5 mM) of each molecule incubated for
72 h.
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Snu182 (9.8±2.48 mM) (Table 3).Whenwecompare their IC50values
with 5-FU, we observed that the newly synthesized compound 36
had comparable and even better. Considering its cytotoxic activity
which is even better than 5-FU, we further analysed the cellular
activity of compound 36 on liver cancer cell lines, Huh7, HepG2,
Mahlavu and FOCUS. Time-dependent cytotoxicities and the IC50
values (for 24, 48, 72 h) of 36 were given in Fig. 7 and Table 4
respectively. Although the purine analogue, 36 induced-
cytotoxicity was similar for all the cell lines at 72 h, the 24 h of in-
cubation, this molecule was not significantly active onMahlavu and
FOCUS cells. The time dependent cytotoxicity data of 36 demon-
strated that this novel purine analogue induces cell-line-dependent
“short term” cytotoxicity; while, the “long term” 36 responses had a
differential activity on the selected liver cancer cells.2.2.3. Real-time cellular response of hepatocellular carcinoma cells
with compound 36 treatment
Real-time Cell Electronic Sensing (RT-CES) system has been used
to evaluate the compound 36 mediated cytotoxicity on Huh7,HepG2, and Mahlavu liver cancer cells in triplicate. The real-time
dynamic monitoring of the electrode impedance indicates a Cell
Index (CI) correlated with cell growth. Compound 36 triggered a
time- and dose-dependent decrease in cell growth indexes in all
HCC cells (Fig. 8). The percent cytotoxicity, clearly demonstrates the
potent inhibitory action of compound 36 depending on the con-
centrations employed (40e2.5 mM). The PTEN protein deficient cell
line Mahlavu was affected least by 36. Mahlavu cells have hyper-
active PI3K/Akt pathway due to PTEN deficiency [42]. Since we
hypothesized that this compound 36 might be a putative kinase-
protein interfering molecule (Fig. 6), the requirement of higher
concentrations of purine analogue 36 to create cytotoxicity on ki-
nase pathway hyperactive Mahlavu cells were rational.2.2.4. The novel, purine analogue 36 induces cellular senescence
Both the time-dependent SRB assays and the real-time cellular
response of liver cancer cells with compound 36 indicated that the
cytotoxic activity of 36 is a “long-term” arising response. This fact
indicates that the cell death type related to themolecular action of36
might be senescence. In order to identify this possibility, we used
Table 3
IC50 values of 17, 28 and 36 against HCC cell line panel: The liver cancer cells were
incubatedwith each analogue for 72 h and the IC50 values are in mM range. NI stands





HCC cell line: IC50 values (mM)
Huh7 3.2 ± 0.07 1.4 ± 0.01 0.2 ± 0.04
HepG2 3.7 ± 0.25 1.2 ± 0.2 0.3 ± 0.01
Hep3B 6.7 ± 0.20 2.9 ± 0.63 0.8 ± 0.45
PLC 10.5 ± 0.40 3.7 ± 0.46 6.4 ± 1.19
SK-Hep1 4.9 ± 0.29 1.7 ± 0.17 0.2 ± 0.01
Mahlavu 2.3 ± 0.06 1.0 ± 0.09 0.1 ± 0.01
FOCUS 2.9 ± 0.27 1.0 ± 0.02 0.2 ± 0.06
Snu182 55.4 ± 4.7 8.4 ± 0.26 9.6 ± 2.48
Snu475 9.6 ± 0.20 5.4 ± 0.49 NI
Fig. 4. Percent cell death in the presence of purine analogues 17 (A), 28 (B) and 36 (C). Compou
96-well plates, with ten different concentrations for 72 h. Following the SRB assay, the cell d
Z. Demir et al. / European Journal of Medicinal Chemistry 89 (2015) 701e720 711Senescence associated-b-galactosidase and BrdU incorporation as-
says in parallel. Huh7 cells plated with cover slips to 6-well plates
were incubatedwith IC50 and IC100 values (Table 2) in the presence of
36, doxorubicin and DMSO-controls for 3 days and 6 days. Doxoru-
bicin was used as a positive control at its senescence-inducing dose
(25 ng/ml) [43]. BrdU (30 mM) was administered to test its incorpo-
ration into cellular DNA of Huh7 cells 24 h prior to the end of 3 days
and 6 days long incubations. Compound 36 treated Huh7 cells
showed senescence associated morphology (Large blue stained cells
(in web version)) and also the blue-stained (SA-b-gal positive) cells
were negative for BrdU incorporation, whereas DMSO-only applied
Huh7 cells were BrdU positive (Small blue cells), proliferating cells
(Fig. 9).3. Conclusion
A series of 9-substituted adenines (4e12), 6-substituted purines
(15e27) and 6,9-disubstituted purine analogues (28e34, 36e41)
were synthesized and their anti-cancer activities were identified.
Among these 36 compounds, N6-(4-trifluoromethylphenyl)pipera-
zine derivative (17) without any substitution at N-9 position and its
9-(p-toluene-sulfonyl)/9-cyclopentyl analogues (28, 36) were
further analysed for their activity against a hepatocellular carcinoma
(HCC) panel due to their promising cytotoxicities. Despite the
observed nuclear condensation and DNA fragmentation features of
apoptosis, decrease in Bcl-2 and Cyt-c protein expression levels and
cleaved-PARP protein levels were not prominent in the presence of
17,28 and36. Compound36,whichwasdesignedas aputative kinase
inhibitor, displayed thebest bioactivitywith IC50valuesless than1mM
on almost all liver cancer cell lines tested; therefore, the further
analysiswere carried onwith 36. The long term (72 h) drug response
of liver cancer cells to the novel, candidate-chemotherapeutic agent,nds 17, 28, 36 and their DMSO controls were administered to the HCC cells, inoculated in
eath percentages were calculated in comparison to DMSO-only treated wells.
Fig. 5. A) Nuclear staining of Huh7 and FOCUS cells treated with purine analogues 17, 28, 36. Each purine analogue was administered to the liver cancer cells plated on coverslips at
their calculated cell line-specific IC50 values for 72 h. CPT; camptothecin was used as positive control. Cells were visualized at 40. B) PARP cleavage in Mahlavu cells treated with
purine analogues 17, 28, 36 at theirIC50 values for 72 h. STS; staurosporine was used as positive control. Calnexin was used as equal loading.
Z. Demir et al. / European Journal of Medicinal Chemistry 89 (2015) 701e720712substituted purine analogue 36, was considerably more effective
comparing to short term (24 h) drug response.
The results this study, indicated that the compound 36 initiates
senescence associated cell death in a dose- and time-dependent
manner which has been described as a therapeutic mode of ac-
tion for small molecule inhibitors recently [44]. Although there had
been reported nucleoside analogues inducing senescence such as
toyocamycin and decitabine, it is rare to identify purine analogues
as a senescence-inducing drug candidate [30,31].Fig. 6. Kinase inhibitory potential of purine analogues 17, 28 and 36. The relative light
units measured after the kinase assay was performed with 20 mg protein from Huh7
and Mahlavu cells treated with the 17, 28 and 36 at their given IC50values (for 72 h).
STS; staurosporine (0.25 mM) was used as positive control.4. Experimental section
4.1. Chemistry
Melting points were recorded with a capillary melting point
apparatus (Electrothermal 9100) and are uncorrected. NMR spectra
were recorded on a VARIAN Mercury 400 FT-NMR spectrometer
(400 for 1H, 100.6 MHz for 13C). TMS was used as internal standard
for the 1H and 13C NMR spectra; values are given in d (ppm) and J
values are in Hz. High resolution mass spectra data (HRMS) were
collected in-house using a Waters LCT Premier XE Mass Spec-
trometer (high sensitivity orthogonal acceleration time-of-flight
instrument) operating in ESI (þ) method, also coupled with an
AQUITY Ultra Performance Liquid Chromatography system (Waters
Corporation, Milford, MA, USA). All compounds have a purity >95%
as measured by these LC-MS analyses. Elemental analyses (C, H, N)
were determined on a Leco CHNS 932 instrument and gave values
within ±0.4% of the theoretical values. Column chromatography
was accomplished on silica gel 60 (40e63mmparticle size). For the
HCl salts of the synthesized compounds, the free bases were dis-
solved in EtOH/MeOH and a few drops of conc. HCl was added. The
chemical reagents used in synthesis were purchased from E. Merck,
Fluka, Sigma and Aldrich.4.1.1. 9-(20-Hydroxyethyl)-9H-adenine (2)
A solution of adenine (1) (0.56 g, 2.07 mmol), ethylene car-
bonate (0.4 g, 4.54 mmol) and a trace of NaOH in DMF (10 ml) was
heated at reflux for 4 h. After evaporation of solvent under reduced
pressure, the crude product was recrystallized from EtOH. Yield:
78%, mp: 239e240 C (Lit. [37] 238.3e240.4 C). 1H NMR (DMSO-
d6) d 3.75 (q, 2H, CH2OH), 4.18 (t, 2H, CH2N), 4.97 (t, 1H, OH), 7.12 (br
s, 2H, NH2), 8.06 (s, 1H, H-8), 8.13 (s, 1H, H-2). 13C NMR (DMSO-d6)
Fig. 7. Time- and dose-dependent percent cytotoxicity in the presence of compound 36. Purine analogue 36 and its DMSO control were administered to the liver cancer cells,
inoculated in 96-well plates, in triplicate with ten different concentrations for 24, 48 and 72 h. Following the SRB assay, the percent cytotoxicities were calculated in comparison to
DMSO-only treated wells.
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6), 152.24 (C-2), 155.91 (C-4). MS (ESIþ) m/z 180.0 (M þ H) (100%).
4.1.2. 9-(20-Chloroethyl)-9H-adenine (3)
A mixture of 9-(20-hydroxyethyl)-9H-adenine (2) (0.19 g,
1.06 mmol) and SOCl2 (7 ml) was heated at reflux for 2 h. Excess
SOCl2 was removed in vacuo and the crude product was recrys-
tallized from EtOH. Yield: 72%, mp: 204e206 C (Lit. [43]
204.4e205.6 C). 1H NMR (DMSO-d6) d 4.11 (t, 2H, CH2N), 4.63 (t,
2H, CH2Cl), 8.54 (s, 1H, H-8), 8.57 (s, 1H, H-2), 9.20 (br s, 2H,
NH2).13C NMR (DMSO-d6) d 42.93 (CH2Cl), 45.37 (CH2N), 117.96 (C-
5), 144.06 (C-8), 145.25 (C-6), 148.62 (C-2), 150.57 (C-4). MS (ESIþ)
m/z 198.2 (M þ H) (100%), 200.3 (M þ Hþ2) (34%).
4.1.3. General procedure for the synthesis of compounds 4e12
To a suspension of 9-(20-chloroethyl)-9H-adenine (3)
(0.5 mmol) in absolute EtOH (5 ml) was added the appropriate
amine/piperazine (excess) and the mixture was refluxed for
8e15 h. The reaction mixture was concentrated in vacuo and the
residue was purified by column chromatography.
4.1.3.1. 9-[2-[20-(N,N-Dimethylamino)ethyl]amino]ethyl-9H-adenine
HCl (4). The compound was prepared from 3 and N,N-Table 4
Time-dependent IC50 values of 36. Compound 36 was applied in triplicates to liver
cancer cells inoculated into 96-well plates and incubated for 24, 48 and 72 h. The
IC50 values are in mM range.
IC50 (mM)
24 h 48 h 72 h
Huh7 2.7 ± 0.31 1.4 ± 0.30 0.6 ± 0.04
HepG2 1.2 ± 0.25 0.8 ± 0.04 0.2 ± 0.04
Mahlavu 50.1 ± 11.66 0.3 ± 0.03 0.2 ± 0.01
FOCUS 16.7 ± 4.1 0.3 ± 0.02 0.1 ± 0.04dimethylethylenediamine according to general procedure and
was purified by column chromatography with EtOAc/MeOH/NH3
(10:5:0.4) as eluent. Yield: 48%, mp: 225e228 C. 1H NMR (DMSO-
d6) d 2.88 (s, 6H, N(CH3)2), 3.41e3.55 (m, 8H, CH2), 3.67 (t, 2H,
Purine-N-CH2), 8.31 (s, 1H, H-8), 8.39 (s, 1H, H-2).13C NMR (DMSO-
d6) d 34.36 (NeCH3), 41.79, 42.99, 46.38 (CH2eN), 52.53 (CH2-pu-
rine N), 118.97 (C-5), 144.54 (C-8), 145.86 (C-6), 149.75 (C-2), 151.21
(C-4). HRMS (ESIþ) m/z calcd for C11H20N7 (M þ H)þ 250.1780,
found 250.1781. Anal. Calcd for C11H19N7.4HCl.0.2C2H5OH.2.0H2O:
C, 31.09; H, 6.45; N, 22.26. Found C, 31.30; H, 6.78; N, 22.24.
4.1.3.2. 9-[2-[20-(N-Ethylamino)ethyl]amino]ethyl-9H-adenine HCl
(5). The compound was prepared from 3 and N-ethylethylenedi-
amine according to general procedure and was purified by column
chromatography with EtOAc/MeOH/NH3 (10:5:0.4) as eluent. Yield:
45%, mp 255e258 C. 1H NMR (DMSO-d6þD2O) d 1.21 (t, 3H, CH3),
2.94e3.04 (m, 4H, CH2), 3.19 (t, 2H, CH2), 3.27 (t, 2H, CH2), 3.59 (t,
2H, CH2), 4.67 (t, 2H, Purin-N-CH2), 8.55 (s, 2H, H-8, H-2). 13C NMR
(DMSO-d6) d 12.00 (CH3), 35.97, 42.60, 43.51. 44.24 (CH2eN), 46.33
(CH2-purine N), 119.04 (C-5), 144.34 (C-8), 146.34 (C-6), 149.80 (C-
2), 151.51 (C-4). HRMS (ESIþ) m/z calcd for C11H20N7 (M þ H)þ
250.1780, found 250.1776. Anal. Calcd for
C11H19N7.4HCl.0.4C2H5OH.0.2H2O: C, 33.97; H, 6.23; N, 23.50.
Found C, 33.81; H, 6.61; N, 23.89.
4.1.3.3. 9-[2-[20-(N-Isopropylamino)ethyl]amino]ethyl-9H-adenine
HCl (6). The compound was prepared from 3 and N-iso-
propylethylenediamine according to general procedure and was
purified by column chromatography with EtOAc/MeOH/NH3
(10:5:0.1) as eluent. Yield: 19.1%, mp 216e218 C. 1H NMR (DMSO-
d6þD2O) d 1.19 (d, 6H, CH3), 3.16e3.34 (m, 5H, CH, CH2), 3.52 (t, 2H,
CH2), 4.58 (t, 2H, Purin-N-CH2), 8.44 (s, 2H, H-8, H-2). HRMS (ESIþ)
m/z calcd for C12H22N7 (M þ H)þ 264.1937, found 264.1934. Anal.
Calcd for C12H21N7.4HCl.0.2C2H5OH.1.0H2O: C, 34.12; H, 6.51; N,
22.46. Found C, 34.37; H, 6.59; N, 22.31.
Fig. 8. Monitored real-time cell growth of Huh7, HepG2 and Mahlavu cells in the
presence of compound 36. Purine analogue 36 and its DMSO control were adminis-
tered to the liver cancer cells, inoculated in E-Plate 96, in triplicates. The cell growth
index was monitored every 30 min in the presence of the five different concentrations
of 36 (40 mM-red, 20 mM-blue, 10 mM-green, 5 mM-pink, 2.5 mM-orange and DMSO
control-black). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 9. SA-b-gal and BrdU incorporation assays in the presence of 36, Huh7 cells (5000 cells/
values (for 72 h) of36, Doxorubicin (25 ng/ml) and DMSO-only for 3 days and 6 days. SA
administered to the cells 24 h prior to the end of 3rd and 6th days of incubation.
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The compoundwas prepared from 3 and N-phenylethylenediamine
according to general procedure and was purified by column chro-
matographywith EtOAc/MeOH/NH3 (10:5:0.1) as eluent. Yield: 20%,
mp 136e139 C. 1H NMR(DMSO-d6) d 2.71 (t, 2H, CH2), 2.90e3.06
(m, 4H, CH2), 4.18 (t, 2H, Purin-N-CH2), 5.38 (t, 1H, Ph-NH),
6.46e6.57 (m, 3H, H-20,60,40), 7.05 (t, 2H, H-30,50, Jo ¼ 7.6 Hz), 7.18
(s, 2H, NH2), 8.12 (s, 1H, purine H-8), 8.13 (s, 1H, H-2). 13C NMR
(DMSO-d6) d 43.50, 43.77.48.39 (CH2eN), 48.85 (CH2-purine N),
112.66, 116.23,119.36 (CH in phenyl),129.52 (NeC in phenyl),141.89
(C-5), 149.57 (C-8), 150.29 (C-6), 152.94 (C-2), 156.60 (C-4). HRMS
(ESIþ) m/z calcd for C15H20N7 (M þ H)þ 298.1780, found 298.1778.
Anal. Calcd for C15H19N7: C, 60.59; H, 6.44; N, 32.97. Found C, 60.77;
H, 6.31; N, 31.16.4.1.3.5. 9-[2-[20-(1-Pyrrolidinyl)ethyl]amino]ethyl-9H-adenine HCl
(8). The compound was prepared from 3 and 1-(2-aminoethyl)
pyrrolidine according to general procedure and was purified by
column chromatography with EtOAc/MeOH/NH3 (10:5:0.35) as
eluent. Yield: 40.2%, mp 185e187 C. 1H NMR (DMSO-d6 þ D2O)
d 1.99 (br s, 4H, pyrrole CH2), 3.08 (br s, 2H, pyrrole NeCH2),
3.40e3.68 (m, 8H, NeCH2, pyrrolidine NeCH2), 4.67 (t, 2H, purin-
N-CH2), 8.54 (s, 2H, H-8, H-2). 13C NMR (DMSO-d6) d 23.29 (pyr-
rolidine NeCH2), 42.98, 46.36. 49.68 (CH2eN), 63.77 (CH2-purine
N), 118.99 (C-5), 144.45 (C-8), 146.02 (C-6), 149.75 (C-2), 151.30 (C-
4). HRMS (ESIþ) m/z calcd for C13H22N7 (M þ H)þ 276.1937, found
276.1934. Anal. Calcd for C13H21N7.4HCl.0.7CH3OH.1.5H2O: C, 34.96;
H, 6.59; N, 20.83. Found C, 34.66; H, 6.29; N, 20.49.4.1.3.6. 9-[2-[20-(4-Morpholinyl)ethyl]amino]ethyl-9H-adenine HCl
(9). The compound was prepared from 3 and 4-(2-aminoethyl)
morpholine according to general procedure and was purified by
column chromatography with EtOAc/MeOH/NH3 (10:5:0.1) as
eluent. Yield: 51.2%, mp 218e220 C. 1H NMR (DMSO-d6 þ D2O)
d 3.10e3.60 (m, 14H, CH2, morpholine CH2), 4.63 (t, 2H, purin-N-
CH2), 8.49 (d, 2H, H-8, H-2). 13C NMR (DMSO-d6) d 33.68 (mor-
pholine NeCH2), 41.14 (morpholine OeCH2), 46.37, 52.08. 53.79
(CH2eN), 63.83 (CH2-purine N), 118.99 (C-5), 144.52 (C-8), 145.87
(C-6), 149.76 (C-2), 151.21 (C-4). HRMS (ESIþ) m/z calcd for
C13H22N7O (M þ H)þ 292.1886, found 292.1876. Anal. Calcd forwell) inoculated into 6-well plates with coverslips were incubated with IC50 and IC100
-b-gal and BrdU incorporation assays were performed in parallel. BrdU (30 mM) was
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Found C, 35.28; H, 5.81; N, 21.12.
4.1.3.7. 9-[2-(4-Methylpiperazin-1-yl)amino]ethyl-9H-adenine HCl
(10). The compound was prepared from 3 and 1-amino-4-
methylpiperazine according to general procedure and was puri-
fied by column chromatography with EtOAc/MeOH/NH3 (10:5:0.1)
as eluent. Yield: 10%, mp 215e218 C. 1H NMR (DMSO-d6þD2O)
d 2.76 (s, 3H, CH3), 2.88e3.60 (m, 10H, CH2, piperazine CH2), 4.57 (t,
2H, purin-N-CH2), 8.47 (d, 2H, H-8, H-2). HRMS (ESIþ)m/z calcd for
C12H21N8 (M þ H)þ 277.1889, found 277.1890. Anal. Calcd for
C12H20N8.4HCl.0.1C2H5OH.1.0H2O: C, 32.94; H, 6.02; N, 25.19. Found
C, 32.98; H, 5.96; N, 24.83.
4.1.3.8. 9-[2-[4-(2-Hydroxyethyl)piperazine-1-yl]ethyl]-9H-adenine
HCl (11). The compound was prepared from 3 and 1-(2-
hydroxyethyl)piperazine, according to general procedure and was
purified by column chromatography with EtOAc/MeOH/NH3
(10:5:0.1) as eluent. Yield: 76.5%, mp 243e246 C. 1H NMR (DMSO-
d6þD2O) d 3.18e3.53 (m,10H, CH2, piperazin CH2), 3.74 (t, 4H, CH2),
4.58 (t, 2H, purine-N-CH2), 8.45 (s, 1H, H-8), 8.49 (s, 1H, H-2). HRMS
(ESIþ)m/z calcd for C13H22N7O (Mþ H)þ 292.1886, found 292.1883.
Anal. Calcd for C13H21N7O.4HCl.1.6CH3OH: C, 35.90; H, 6.48; N,
20.07. Found C, 35.95; H, 6.10; N, 19.71.
4.1.3.9. 9-[2-[4-[2-(Morpholine-4-yl)ethyl]piperazine-1-yl]ethyl]-
9H-adenine HCl (12). The compound was prepared from 3 and 1-
[2-(morpholine-4-yl)ethyl]piperazine, according to general proce-
dure and was purified by column chromatography with CHCl3/
MeOH/NH3 (10:3:0.1) as eluent. Yield: 39.7%, mp 265e268 C. 1H
NMR (DMSO-d6þD2O) d 2.94e3.48 (m, 22H, CH2, piperazin CH2,
morpholine CH2), 4.60 (t, 2H, purine-N-CH2), 8.46 (s, 1H, H-8), 8.57
(s, 1H, H-2). HRMS (ESIþ) m/z calcd for C17H29N8O (M þ H)þ
361.2464, found 361.2460. Anal. Calcd for C17H28N8O.5HCl.0.6-
H2O.0.5C2H5OH: C, 37.40; H, 6.50; N, 19.43. Found C, 37.11; H, 6.34;
N, 19.21.
4.1.4. 6-Chloro-9-p-toluenesulfonyl-9H-purine (14)
A solution of KOH (360mg, 6mmol) inwater (15ml) and then p-
toluensulfonyl chloride (144 mg, 6 mmol) were added dropwise to
a stirred mixture of 6-chloropurine (13) (464 mg, 3 mmol) in
acetone (35 ml) at 0 C. The mixture was stirred at 0 C 8 h and
acetone was removed in vacuo. The solid was filtered off, washed
with water and recrystallized from EtOH to yield 14 (650 mg;
70.1%): mp 172e175 C. 1H NMR (DMSO-d6) d 2.39 (s, 3H, CH3), 7.53
(d, 2H, H-30,50, Jo ¼ 8.4 Hz), 8.14 (d, 2H, H-20,60, Jo ¼ 8.4 Hz), 8.91 (s,
1H, purine H-8), 9.16 (s, 1H, purine H-2). HRMS (ESIþ)m/z calcd for
C12H10ClN4O2S (M þ H)þ 309.0213, found 309.0206. Anal. Cald for
C12H9ClN4O2S.0.4H2O: C, 45.62; H, 3.13; N, 17.73; S, 10.15. Found C,
45.91; H, 3.52; N, 18.11; S, 10.51.
4.1.5. General procedure A for the synthesis of 6-substituted purines
(15, 16, 18, 21, 22, 28)
6-Chloropurine (13) was dissolved in 5 ml absolute EtOH, then
the appropriate amine/piperazine/4-methylpiperidine and (Et)3N
(1.7 equiv) were added. The mixture was refluxed for 8e40 h. The
reaction mixture was concentrated in vacuo and the residue was
crystallized from EtOH.
4.1.6. General procedure B for the synthesis of 6-substituted purines
(17, 23e27, 29)
A solution of 6-chloropurine (13) in 7 ml of n-BuOH was stirred
at 70e80 C for 0.5 h then the appropriate amine/piperazine and
(Et)3N (1.7 equiv) were added. The mixture was heated at 90 C for
4 h. After cooling, the precipitated product was filtered off, washedwith cold water and n-BuOH. The product was crystallized from
EtOH.
4.1.7. 6-[4-(2-Hydroxyethyl)piperazine-1-yl]-9H-purine (15)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and N-(2-hydroxyethyl)piperazine (0.3 ml, 2.45 mmol)
according to general procedure A to yield 15 (228 mg, 71%): mp
230e234 C. 1H NMR (DMSO-d6þD2O) d 2.44 (t, J ¼ 6.4 Hz, 2H,
NCH2), 2.53 (t, 4H, piperazine CH2), 3.55 (t, J ¼ 6.4 Hz, 2H, OCH2),
4.21 (br s, 4H, piperazine CH2), 8.11 (s, 1H, H-8), 8.20 (s, 1H, H-2).
HRMS (ESIþ) m/z calcd for C11H17N6O (M þ H)þ 249.1464, found
249.1455. Anal. Calcd for C11H16N6O: C, 53.21; H, 6.50; N, 33.85.
Found C, 53.14; H, 6.13; N, 33.52.
4.1.8. 6-(1-Formylpiperazine-4-yl]-9H-purine (16)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 1-piperazinecarboxaldehyde (0.2 ml, 1.94) ac-
cording to general procedure A and the product was purified by
column chromatography (CHCl3/MeOH 10:3) to yield 16 (179 mg,
60%): mp 218e222 C. 1H NMR (DMSO-d6) d 3.38e3.56 (m, 6H,
piperazine CH2), 4.24 (br d, 2H, piperazine CH2), 8.07 (s, 1H, H-8),
8.12 (s, 1H, H-2), 8.17 (s, 1H, CHO), 8.25 (s, 1H, purine NH). HRMS
(ESIþ) m/z calcd for C10H13N6O (M þ H)þ 233.1151, found 233.1147.
Anal. Calcd for C10H12N6O: C, 51.72; H, 5.21; N, 36.19. Found C, 51.82;
H, 5.59; N, 36.48.
4.1.9. 6-[4-(4-Trifluorophenyl)piperazin-1-yl]-9H-purine (17)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and N-(a,a,a-trifluoro-p-tolyl)piperazine (297 mg,
1.29 mmol) according to general procedure B to yield 17 (394 mg,
87.6%): mp 286e289 C. 1H NMR (DMSO-d6) d 3.44 (t, 4H, pipera-
zine CH2), 4.37 (br s, 4H, piperazine CH2), 7.13 (d, Jo ¼ 8.8 Hz, 2H, H-
20,60), 7.54 (d, Jo ¼ 8.8 Hz, 2H, H-30,50), 8.17 (s, 1H, purine H-8), 8.25
(s,1H, purine H-2),13.08 (br s,1H, NH). 13C NMR (DMSO-d6) d 44.03,
46.92 (CH2 in piperazine), 114.29, 118.01 (q), 118.82 123.54 (C in
phenyl), 126.11 (q) (CF3), 138.29 (C-5), 151.41 (C-8), 151.73 (C-6),
152.99 (C-2), 153.10 (C-4). HRMS (ESIþ) m/z calcd for C16H16F3N6
(M þ H)þ 349.1389, found 349.1380. Anal. Calcd for C16H15F3N6: C,
55.17; H, 4.34; N, 24.13; Found C, 55.00; H, 4.36; N, 24.19.
4.1.10. 6-(4-Methylpiperidin-1-yl)-9H-purine (18)
The compound was prepared from 6-chloropurine (13) (100 mg,
0.65 mmol) and 4-methylpiperidine (0.1 ml, 0.84 mmol) according
to general procedure A to yield 18 [24] (72 mg, 51.4%): mp264-
266 C. 1H NMR (DMSO-d6)d 0.92 (d, 3H, CH3),1.04e1.16 (m, 1H,
piperidine CH), 1.72 (br d, 4H, piperidine CH2), 3.03 (t, 4H, piperi-
dine NeCH2), 8.09 (s, 1H, H-8), 8.18 (s, 1H, H-2), 13.00 (br s, 1H, NH).
HRMS (ESIþ) m/z calcd for C11H16N5 (M þ H)þ 218.1406, found
218.1411. Anal. Calcd for C11H15N5: C, 60.81; H, 6.96; N, 32.23.
4.1.11. 6-Cyclopropylamino-9H-purine (19)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and cyclopropylamine (0.2 ml, 2.85 mmol) according to
general procedure A to yield 19 [45] (108 mg, 47.9%): mp230-
233 C. 1H NMR (DMSO-d6) d 0.61e0.65 (m, 2H, CH2), 0.69e0.78 (m,
2H, CH2), 3.03 (br s, 1H, NH), 8.05 (br s, 1H, purine NH), 8.15 (s, 1H,
H-8), 8.26 (s, 1H, H-2). HRMS (ESIþ)m/z calcd for C8H10N5 (MþH)þ
176.0936, found 176.0931. Anal. Cald for C8H9N5.0.4H2O: C, 52.67;
H, 5.41; N, 38.39. Found C, 52.29; H, 5.18; N, 38.45.
4.1.12. 6-(2-Hydroxyethyl)amino-9H-purine (20)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 2-aminoethanol (0.1 ml, 1.64 mmol) according to
general procedure A to yield 20 [46] (194 mg, 83.7%): mp
247e250 C. 1H NMR (DMSO-d6) d 3.57 (br s, 4H, CH2), 4.82 (br s,1H,
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HRMS (ESIþ) m/z calcd for C7H10N5O (M þ H)þ 180.0885, found
180.0877.
4.1.13. 6-(4-Methoxybenzyl)amino-9H-purine (21)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol)and 4-(methoxybenzyl)amine (0.25 ml, 1.91 mmol) ac-
cording to general procedure B to yield 21 [47] (260 mg, 78.8%): mp
246e250 C. 1H NMR (DMSO-d6þD2O) d 3.71 (s, 3H, OCH3), 4.64 (br
s, 2H, CH2), 6.87 (d, Jo ¼ 8.4 Hz, 2H, H-30,50), 7.30 (d, Jo ¼ 8.4 Hz, 2H,
H-20,60), 8.11 (s, 1H, purine H-8), 8.19 (s, 1H, purine H-2). HRMS
(ESIþ)m/z calcd for C13H14N5O (M þ H)þ 256.1198, found 256.1188.
Anal. Cald for C13H13N5O.0.2H2O: C, 60.31; H, 5.21; N, 27.05. Found
C, 60.21; H, 5.02; N, 26.78.
4.1.14. 6-[3-(Trifluoromethyl)benzyl]amino-9H-purine (22)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 3-(trifluoromethyl)benzylamine (0.25 ml,
1.75 mmol) according to general procedure B to yield 22 (200 mg,
52.7%): mp 250e253 C. 1H NMR (DMSO-d6) d 4.78 (br s, 2H, CH2),
7.52e7.71 (m, 4H, H-Ph), 8.15 (d, 2H, purine H-8, H-2), 8.35 (br s,1H,
NH), 12.96 (br s, 1H, purine NH). 13C NMR (DMSO-d6) d 43.20 (CH2),
123.61, 124.0 (q), 124.34 (q), 126.33, 129.41, 129.72 (C in phenyl),
129.94 (CF3), 132.03 (C-5), 139.75 (C-8), 142.51 (C-6), 153.0 (C-2),
154.79 (C-4). HRMS (ESIþ) m/z calcd for C13H11F3N5 (M þ H)þ
294.0967, found 294.0963. Anal. Cald for C13H10F3N5: C, 53.24; H,
3.44; N, 23.88. Found C, 53.13; H, 3.47; N, 23.76.
4.1.15. 6-(2,4-Difluorobenzyl)amino-9H-purine (23)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 2,4-difluorobenzylamine (0.2 ml, 1.68 mmol) ac-
cording to general procedure B to yield 23 [47] (255 mg, 75.8%): mp
263e265 C. 1H NMR (DMSO-d6) d 4.68 (br s, 2H, CH2), 6.98 (t,
Jo¼ 8.4 Hz,1H, H-30), 7.18 (t, Jo¼ 8.4 Hz,1H, H-50), 7.35 (d, Jo¼ 7.2 Hz
1H, H-60), 8.12 (d, 3H, purine H-8, H-2, NH), 12.91 (br s, 1H, purine
NH). 13C NMR (DMSO-d6) d37.13 (CH2), 104.20 (t), 111.83 (C in
phenyl), 123.70 (C-5), 130.94 (C-8), 139.78 (C-6), 152.97 (C-2),
154.85 (C-4), 159.44, 160.66, 161.77, 163.03 (C in phenyl). HRMS
(ESIþ) m/z calcd for C12H10F2N5 (M þ H)þ 262.0904, found
262.0903. Anal. Cald for C12H9F2N5: C, 55.17; H, 3.47; N, 26.81.
Found C, 55.49; H, 3.53, N, 26.67.
4.1.16. 6-(2,4-Dichlorobenzyl)amino-9H-purine (24)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 2,4-dichlorobenzylamine (0.23 ml, 1.73 mmol)
according to general procedure B to yield 24 [47] (353 mg,
92.9%):mp 286e290 C. 1H NMR (DMSO-d6) d 4.71 (br s, 2H, CH2),
7.28 (d, Jo ¼ 8.4 Hz 1H, H-60), 7.36 (dd, Jo¼ 8 Hz, Jm ¼ 2 Hz,1H, H-50),
7.61 (d, Jm ¼ 1.6 Hz, 1H, H-30), 8.15 (s, 2H, purine H-8, H-2), 8.28 (br
s, 1H, NH), 12.98 (br s, 1H, purine NH). HRMS (ESIþ) m/z calcd for
C12H10Cl2N5 (M þ H)þ 294.0313, found 294.0317. Anal. Cald for
C12H9Cl2N5.0.2CH3OH: C, 48.75; H, 3.29; N, 23.30. Found C, 48.60;
H, 2.99; N, 22.95.
4.1.17. 6-[2-(N-Phenylamino)ethyl]amino-9H-purine (25)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and N-phenylethlenediamine (0.2 ml, 1.53 mmol) ac-
cording to general procedure B to yield 25 [24] (290 mg, 88.1%): mp
253e255 C. 1H NMR (DMSO-d6) d3.31 (q, 2H, CH2),3.72 (br s, 2H,
CH2), 5.84 (t, 1H, NH), 6.57 (t, Jo ¼ 7.2 Hz, 1H, H-40), 6.68 (d,
Jo¼ 8.4 Hz, 2H, H-20,60), 7.13 (t, Jo¼ 7.6 Hz, 2H, H-30,50), 7.79 (br s,1H,
NH), 8.16 (s, 1H, purine H-8), 8.28 (s, 1H, purine H-2), 13.00 (br s,1H,
purine NH). HRMS (ESIþ) m/z calcd for C13H15N6 (M þ H)þ
255.1358, found 255.1350. Anal. Calcd for C13H14N6: C, 61.40; H,
5.55; N, 33.05. Found C, 61.04; H, 5.46; N, 32.95.4.1.18. 6-(2-Cyclohexenylethyl)amino-9H-purine (26)
The compound was prepared from 6-chloropurine (13) (150 mg,
0.97 mmol) and 2-(1-cyclohexenyl)ethylamine (0.27 ml,
1.94 mmol) according to general procedure A and the product was
purified by column chromatography (EtOAc/MeOH 10:1) to yield 26
[24] (160 mg, 68%): mp 197e200 C. 1H NMR (DMSO-d6) d1.51 (dd,
4H, CH2), 1.94 (d, 4H, CH2), 2.22 (t, 2H, CH2), 3.55 (br s, 2H,
NHeCH2), 5.41 (s, 1H, ]CH), 7.52 (br s, 1H, NH), 8.07 (s, 1H, purine
H-8), 8.17 (s, 1H, purine H-2), 12.88 (br s, 1H, purine NH). HRMS
(ESIþ) m/z calcd for C13H18N5 (M þ H)þ 244.1562, found 244.1553.
Anal.Calcd for C13H17N5: C, 64.17; H, 7.04; N, 28.78. Found C, 63.85;
H, 6.65; N, 28.39.
4.1.19. 6-(1-Benzylpiperidine-4-yl)amino-9H-purine (27)
The compoundwas prepared from 6-chloropurine (13) (200mg,
1.29 mmol) and 4-amino-1-benzylpiperidine (0.35 ml, 1.71 mmol)
according to general procedure B to yield 27 (170 mg, 42.6%): mp
279e282 C. 1H NMR (DMSO-d6) d 1.87e2.20 (m, 4H, piperidine
3,5-CH2), 3.00e3.26 (m, 4H, piperidine 2,6-CH2), 4.28 (br s, 3H,
piperidine 4-CH, benzyl CH2), 7.46 (s, 3H, H-20,40,60), 7.59 (s, 2H, H-
30,50), 7.87 (br s, 1H, NH), 8.17 (d, 2H, purine H-8, H-2), 12.99 (br s,
1H, purine NH). HRMS (ESIþ) m/z calcd for C17H21N6 (M þ H)þ
309.1828, found 309.1819. Anal. Calcd for C17H20N6: C, 66.21; H,
6.54; N, 27.25. Found C, 66.48; H, 6.17; N, 27.54.
4.1.20. General procedure for the sulfonylation of 6-substituted
purines (preparation of compounds 28e34)
A solution of p-toluenesulfonylchloride (2 equiv) in 5 ml CH2Cl2
was slowly added to a solution of 6-substituted purines (28e34) in
1 ml pyridine. The reaction mixture was stirred for 24 h in an ice
bath. The reaction mixture was treated with 1 N HCl (5 ml) and
extracted with CH2Cl2. The extract was dried over Na2SO4, the
solvent was evaporated in vacuo, and the residue was purified by
column chromatography.
4.1.20.1. 6-[4-(4-Trifluoromethylphenyl)piperazin-1-yl]-9-p-toluene-
sulfonyl-9H-purine (28). The compound was prepared from 6-[4-
(4-Trifluorophenyl)piperazin-1-yl]-9H-purine (17) (230 mg,
0.66 mmol) according to general procedure and was purified by
column chromatography (EtOAc-hexane, 1:1) to yield 28 (170 mg;
50.6%): mp 219e221 C. 1H NMR (DMSO-d6) d 2.39 (s, 3H, CH3), 3.43
(t, 4H, piperazine CH2), 4.31 (br s, 4H, piperazine CH2), 7.10 (d,
Jo ¼ 8.4 Hz, 2H, H-20,60), 7.51 (m, 4H, H-30,50, p-toluene H-3,5), 8.10
(d, Jo¼ 8.4 Hz, 2H, p-toluene H-2,6), 8.35 (s, 1H, purine H-2), 8.71 (s,
1H, purine H-8). 13C NMR (DMSO-d6) d 21.85 (CH3), 45.08, 47.42
(CH2 in piperazine), 114.98, 118.80 (q), 119.83, 124.24 (C in phenyl),
126.88 (q) (CF3), 128.87, 130.97, 134.02 (C in phenyl), 137.92 (C-5),
147.46 (C in phenyl), 150.09 (C-8), 153.63 (C-6), 153.78 (C-2), 154.25
(C-4). HRMS (ESIþ)m/z calcd for C23H22F3N6O2S (MþH)þ 503.1477,
503.1472. Anal. Calcd for C23H21F3N6O2S: C, 54.97; H, 4.21; N, 16.72;
S, 6.38; Found C, 54.75; H, 4.13; N, 16.53; S, 6.25.
4.1.20.2. 6-(4-Methylpiperidin-1-yl)-9-p-toluenesulfonyl-9H-purine
(29). The compound was prepared from 6-(4-methylpiperidin-1-
yl)-9H-purine (18) (100 mg, 0.46 mmol) according to general pro-
cedure and was purified by column chromatography (EtOAc-hex-
ane, 1:2) to yield 29 (110 g, 62%): mp 156e157 C. 1H NMR(DMSO-
d6)d 0.89 (d, 3H, piperidine CH3), 1.00e1.14 (m, 1H, piperidine CH),
1.71 (d, 4H, piperidine CH2), 2.39 (s, 3H, CH3), 2.96e3.12 (br s, 4H,
piperidine NeCH2), 7.50 (d, Jo ¼ 8 Hz, 2H, p-toluene H-3,5), 8.09 (d,
Jo ¼ 8.4 Hz, 2H, p-toluene H-2,6), 8.28 (s, 1H, purine H-2), 8.64 (s,
1H, purine H-8). 13C NMR (DMSO-d6) d 21.85, 22.26 (CH3), 31.07,
34.38, 45.54 (CH2 in piperidine), 119.62, 128.90, 130.96, 134.08 (C in
phenyl), 137.36 (C-5), 147.40 (C-8), 150.05 (C-6), 153.67 (C-2), 154.27
(C-4). HRMS (ESIþ) m/z calcd for C18H22N5O2S (M þ H)þ 372.1494,
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18.85; S, 8.63. Found C, 58.51; H, 5.84; N, 19.00; S, 8.70.
4.1.20.3. 6-Cyclopropylamino-9-p-toluenesulfonyl-9H-purine (30).
The compound was prepared from 6-cyclopropylamino-9H-purine
(19) (90 mg, 0.51 mmol) according to general procedure and was
purified by column chromatography (EtOAc-hexane, 1:1) to yield
30 (47 mg, 27.8%): mp 173e176 C. 1H NMR (DMSO-d6) d 0.58e0.76
(m, 4H, CH2), 2.38 (s, 3H, CH3), 7.50 (d, Jo ¼ 9.2 Hz, 2H, p-toluene H-
3,5), 8.09 (d, Jo ¼ 8.8 Hz, 2H, p-toluene H-2,6), 8.34 (br s, 2H, purine
H-2, NH), 8.63 (s, 1H, purine H-8). 13C NMR (DMSO-d6) d 7.45 (CH2
in cyclopropyl), 21.87 (CH3), 24.25 (CH in cyclopropyl), 119.85,
128.76, 131.0, 134.24 (C in phenyl), 138.70 (C-5), 147.36 (C-8), 148.47
(C-6), 154.97 (C-2), 156.37 (C-4). HRMS (ESIþ) m/z calcd for
C15H16N5O2S (M þ H)þ 330.1025, found 330.1033. Anal. Calcd for
C15H15N5O2S.0.1C6H14: C, 55.43; H, 4.89; N, 20.72; S, 9.48; Found C,
55.43; H, 4.99; N, 21.04; S, 9.49.
4.1.20.4. 6-(4-Methoxybenzyl)amino-9-p-toluenesulfonyl-9H-purine
(31). The compound was prepared from 6-(4-methoxybenzyl)
amino-9H-purine (21) (100 mg, 0.39 mmol) according to general
procedure and was purified by column chromatography (EtOAc-
hexane, 1:1) to yield 31 (27 mg, 16.9%): mp 163e165 C. 1H NMR
(DMSO-d6) d 2.35 (s, 3H, CH3), 3.66 (s, 3H, OCH3), 4.56 (d, 2H, CH2),
6.80 (d, Jo¼ 8.4 Hz, 2H, H-30,50), 7.21 (d, Jo¼ 8.4 Hz, 2H, H-20,60), 7.46
(d, Jo ¼ 8.4 Hz, 2H, p-toluene H-3,5), 8.06 (d, Jo ¼ 8.4 Hz, 2H, p-
toluene H-2,6), 8.26 (s, 1H, purine H-2), 8.60 (s, 1H, purine H-8),
8.66 (br s, 1H, NH). 13C NMR (DMSO-d6) d 21.85 (CH3), 43.08 (CH2),
55.66 (OCH3), 114.29, 119.89, 128.76, 129.22, 130.99, 132.05, 134.20
(C in phenyl), 138.85 (C-5), 147.37 (C-8), 148.36 (C-6), 155.01 (C-2),
155.08 (C-4), 158.83 (C in phenyl). HRMS (ESIþ) m/z calcd for
C20H20N5O3S (M þ H)þ 410.1287, found 410.1279. Anal. Calcd for
C20H19N5O3S: C, 58.67; H, 4.68; N, 17.10; S, 7.83; Found C, 58.82; H,
4.95; N, 16.88; S, 7.72.
4.1.20.5. 6-(2,4-Difluorobenzyl)amino-9-p-toluenesulfonyl-9H-pu-
rine (32). The compound was prepared from 6-(2,4-
difluorobenzyl)amino-9H-purine (23) (150 mg, 0.57 mmol) ac-
cording to general procedure and was purified by column chro-
matography (EtOAc-hexane, 1:2) to yield 32 (70 mg, 29.3%): mp
153e156 C. 1H NMR (DMSO-d6) d 2.38 (s, 3H, CH3), 4.67 (br s, 2H,
CH2), 6.98 (t, 1H, H-30), 7.19 (t, 1H, H-50), 7.35 (q, 1H, H-60), 7.50 (d,
Jo ¼ 8.4 Hz, 2H, p-toluene H-3,5), 8.10 (d, Jo ¼ 8 Hz, 2H, p-toluene H-
2,6), 8.30 (s, 1H, purine H-2), 8.67 (s, 1H, purine H-8), 8.75 (br s, 1H,
NH). HRMS (ESIþ)m/z calcd for C19H16 F2N5O2S (Mþ H)þ 416.0993,
found 416.0978. Anal. Calcd for C19H15F2N5O2S: C, 54.93; H, 3.64; N,
16.86; S, 7.72; Found C, 55.26; H, 3.87; N, 16.86; S, 7.61.
4.1.20.6. 6-(2,4-Dichlorobenzyl)amino-9-p-toluenesulfonyl-9H-pu-
rine (33). The compound was prepared from 6-(2,4-
dichlorobenzyl)amino-9H-purine (24) (100 mg, 0.33 mmol) ac-
cording to general procedure and was purified by column chro-
matography (EtOAc-hexane, 1:2) to yield 33 (40 mg, 23.7%): mp
180e183 C. 1H NMR (DMSO-d6) d 2.39 (s, 3H, CH3), 4.67 (d, 2H,
CH2), 7.24 (d, 1H, H-60), 7.31 (d, 1H, H-50), 7.51 (d, Jo ¼ 8.4 Hz, 2H, p-
toluene H-3,5), 7.61 (s, 1H, H-30), 8.11 (d, Jo ¼ 7.6 Hz, 2H, p-toluene
H-2,6), 8.28 (s, 1H, purine H-2), 8.70 (s, 1H, purine H-8), 8.79 (br s,
1H, NH). 13C NMR (DMSO-d6) d 21.87 (CH3), 41.43 (CH2), 120.02,
127.96, 128.84, 129.21, 130.22, 131.03, 132.70, 133.33, 134.14, 136.09
(C in phenyl), 139.19 (C-5), 147.46 (C-8), 148.42 (C-6), 154.97 (C-2),
155.06 (C-4). HRMS (ESIþ) m/z calcd for C19H16Cl2N5O2S (M þ H)þ
448.0402, found 448.0408. Anal. Calcd for C19H15Cl2N5O2S: C,
50.90; H, 3.37; N, 15.62; S, 7.15. Found C, 51.04; H, 3.42; N, 15.44; S,
7.17.4.1.20.7. 6-(2-Cyclohexenylethyl)amino-9-p-toluenesulfonyl-9H-pu-
rine (34). The compound was prepared from 6-(2-
cyclohexenylethyl)amino-9H-purine (26) (80 mg, 0.32 mmol) ac-
cording to general procedure and was purified by column chro-
matography (EtOAc-hexane, 1:2.5) to yield 34 (17 mg, 12.8%): mp
161e163 C.1H NMR (DMSO-d6) d 1.51 (d, 4H, CH2), 1.88 (d, 4H, CH2),
2.16 (t, 2H, CH2), 2.38 (s, 3H, CH3), 3.51 (q, 2H, NHeCH2), 5.36 (s,
1H, ¼CH), 7.50 (d, Jo ¼ 8.4 Hz, 2H, p-toluene H-3,5), 8.08 (d, 3H, p-
toluene H-2,6, NH), 8.28 (s, 1H, purine H-2), 8.61 (s, 1H, purine H-8).
13C NMR (DMSO-d6) d 21.85 (CH3), 22.55, 23.06, 25.31, 28.44 (CH2 in
cyclohexenyl), 37.81 (CH2), 39.09 (NHeCH2), 119.83 (C in phenyl),
122.57 (¼CH in cyclohexenyl), 128.74, 130.98, 134.21 (C in phenyl),
135.60 57 (C ¼ in cyclohexenyl), 138.66 (C-5), 147.34 (C-8), 148.21
(C-6), 155.07 (C-2), 155.26 (C-4). HRMS (ESIþ) m/z calcd for
C20H24N5O2S (M þ H)þ 398.1651, found 398.1649. Anal. Calcd for
C20H23N5O2S: C, 60.43; H, 5.83; N, 17.62; S, 8.07. Found C, 60.45; H,
6.09; N, 17.36; S, 7.95.
4.1.21. 6-[4-(4-Trifluorophenyl)piperazin-1-yl]-9-cyclopentyl-9H-
purine (36)
To a suspension of 6-chloro-9-cyclopentyl-9H-purine (35) [24]
(106 mg, 0.47 mmol) in absolute EtOH (5 ml) was added N-(a,a,a-
trifluoro-p-tolyl)piperazine (109.6 mg, 0.47 mmol) and the mixture
was refluxed for 10 h. The reaction mixture was concentrated in
vacuo and the residue was purified by column chromatography
(EtOAc-hexane, 1:4 and 1:2) to yield 36 (140 mg, 70.6%): mp143-
145 C. 1H NMR (CDCl3) d 1.79e2.01 (m, 6H, cyclopentyl CH2),
2.24e2.34 (m, 2H, cyclopentyl CH2), 3.42 (t, 4H, piperazine CH2),
4.48 (br s, 4H, piperazine CH2), 4.91e4.98 (m, 1H, cyclopentyl CH),
6.98 (d, Jo¼ 8.4 Hz, 2H, H-20,60), 7.51 (d, Jo¼ 8.4 Hz, 2H, H-30,50), 7.82
(s, 1H, purine H-2), 8.39 (s, 1H, purine H-8). 13C NMR (DMSO-d6)
d 24.02, 32.95 (CH2 in cyclopentyl),44.93, 48.49 (CH2 in piperazine),
55.95 (CH2 in cyclopentyl), 115.07, 120.60, 121.21 (q), 123.53 (C in
phenyl), 126.71 (q) (CF3), 136.93 (C-5), 151.32 (C-8), 152.33 (C-6),
153.44 (C-2), 153.97 (C-4). HRMS (ESIþ) m/z calcd for C21H24F3N6
(M þ H)þ 417.2015, found 417.2012. Anal. Calcd for
C21H23F3N6.0.1H2O: C, 60.30; H, 5.59; N, 20.09. Found C, 59.99; H,
5.64; N, 20.21.
4.1.22. General procedure for the alkylation of 6-substituted purines
(preparation of compounds 38e41)
To a suspension of 6-substituted purines (15, 17, 22, 24) in dry
DMF (5 ml) was added NaH (2 equiv, 95%) and the mixture was
stirred for 0.5 h at rt. Subsequently, ethyl chloroacetate (3 equiv)
was added and the reaction mixture was left for 24 h at rt. The
reaction mixture was treated with water and extracted with ether.
The extract was dried over Na2SO4, the solvent was evaporated in
vacuo, and the residue was purified by column chromatography.
4 .1. 22 .1. 6 - ( 3 -Tr ifluo rome thyben zy l ) am ino -9 - ( e t hox -
ycarbonylmethyl)-9H-purine (38). The compound was prepared
from 6-(3-trifluoromethybenzyl)amino-9H-purine (22) (110 mg,
0.37 mmol) according to general procedure and was purified by
column chromatography (EtOAc-hexane, 5:1) to yield 37 (34 mg,
23.9%): mp 184e188 C. 1H NMR (DMSO-d6) d 1.21 (t, J¼ 6.8 Hz, 3H,
CH3), 4.16 (q, J ¼ 6.8 Hz, 2H, OCH2), 4.79 (br s, 2H, benzyl CH2), 5.09
(s, 2H, NCH2), 7.52e7.62 (m, 2H, H-40,60), 7.66 (d, 1H, H-50), 7.72 (s,
1H, H-20), 8.17 (s, 1H, H-8), 8.20 (s, 1H, H-2), 8.52 (br s, 1H, NH).
HRMS (ESIþ) m/z calcd for C17H17F3N5O2 (M þ H)þ 380.1334, found
380.1331. Anal. Calcd for C17H16F3N5O2.0.1C6H14.0.1H2O: C, 54.24; H,
4.55; N, 17.97. Found C, 54.07; H, 4.39; N, 17.72.
4.1.22.2. 6-(2,4-Dichlorobenzyl)amino-9-(ethoxycarbonylmethyl)-
9H-purine (39). The compound was prepared from 6-(2,4-
dichlorobenzyl)amino-9H-purine (24) (100 mg, 0.33 mmol)
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matography (EtOAc-hexane, 1:1) to yield 38 (30 mg, 23.2%): mp
199e203 C. 1H NMR (DMSO-d6) d 1.21 (t, 3H, CH3), 4.15 (q, 2H,
OCH2), 4.70 (br s, 2H, benzyl CH2), 5.07 (s, 2H, NCH2), 7.27 (d,
Jo¼ 8 Hz,1H, H-60), 7.34 (dd, Jo¼ 8 Hz, Jm¼ 1.6 Hz,1H, H-50), 7.59 (d,
Jm ¼ 2 Hz, 1H, H-30), 8.16 (s, 2H, H-8, H-2), 8.41 (br s, 1H, NH). 13C
NMR (DMSO-d6) d 14.68 (CH3), 41.54 (NHeCH2), 44.65 (CH2-purine
N), 62.07 (OeCH2), 127.96, 129.18, 130.12, 132.57 (C in phenyl),
133.30 (C-5),136.75 (C-8), 142.25 (C-6), 153.24 (C-2), 154.82 (C-4),
168.61 (C]O). HRMS (ESIþ) m/z calcd for C16H16Cl2N5O2 (M þ H)þ
380.0681, found 380.0670. Anal. Calcd for C16H15Cl2N5O2.0.2C6H14:
C, 51.97; H, 4.51; N, 17.62. Found C, 51.84; H, 4.21; N, 17.25.
4.1.22.3. 6-[4-(2-Hydroxyethyl)piperazine-1-yl]-9-(ethox-
ycarbonylmethyl)-9H-purine (40). The compound was prepared
from 6-[4-(2-hydroxyethyl)piperazine-1-yl]-9H-purine (15)
(100 mg, 0.40 mmol) according to general procedure and was pu-
rified by column chromatography (CH2Cl2eMeOH, 2.5:1) to yield
39 (35 mg, 26%): mp 118e120 C. 1H NMR (DMSO-d6) d 1.22 (t, 3H,
CH3), 2.43 (t, J ¼ 6 Hz, 2H, CH2eCH2eOH), 2.53 (t, 4H, piperazine
CH2), 3.54 (q, J ¼ 6 Hz, 2H, CH2OH), 4.04e4.32 (m, 6H, piperazine
CH2, OCH2), 4.48 (t, 1H, OH), 5.09 (s, 2H, NCH2), 8.17 (s, 1H, H-8),
8.23 (s, 1H, H-2). 13C NMR (DMSO-d6) d 14.68 (CH3), 44.65, 45.07
(CH2 in piperazine),53.84 (CH2eN), 59.11(CH2-purine N), 60.91
(CH2eOH), 62.04 (OeCH2), 119.19 (C-5), 141.04 (C-8), 151.46 (C-6),
152.68 (C-2), 153.79 (C-4),168.55 (C]O). HRMS (ESIþ)m/z calcd for
C15H23N6O3 (M þ H)þ 335.1832, found 335.1827. Anal. Calcd for
C15H22N6O3.0.46CH2Cl2: C, 49.72; H, 6.19; N, 22.50. Found C, 49.33;
H, 6.91; N, 22.79.
4.1.22.4. 6-[4-(4-Trifluorophenyl)piperazin-1-yl]-9-(ethox-
ycarbonylmethyl)-9H-purine (41). The compound was prepared
from 6-[4-(4-trifluorophenyl)piperazin-1-yl]-9H-purine (17)
(100 mg, 0.29 mmol) according to general procedure and was pu-
rified by column chromatography (EtOAc- hexane, 1:1) to yield 40
(30 mg, 24.1%): mp 216e218 C. 1H NMR (DMSO-d6) d 1.23 (t, 3H,
CH3), 3.46 (t, 4H, piperazine CH2), 4.17 (q, J¼ 6.8 Hz, 2H, OCH2), 4.37
(br s, 4H, piperazine CH2), 5.11 (s, 2H, NCH2), 7.14 (d, Jo ¼ 8.4 Hz, 2H,
H-20,60), 7.54 (d, Jo ¼ 8.4 Hz, 2H, H-30,50), 8.22 (s, 1H, H-8), 8.28 (s,
1H, H-2). 13C NMR (DMSO-d6) d 14.33 (CH3), 44.34, 44.95 (CH2 in
piperazine),48.48 (CH2-purine N), 62.54 (OeCH2), 115.09, 119.69,
121.23 (q), 123.46 (C in phenyl), 126.73 (q) (CF3), 139.11 (C-5), 151.37
(C-8), 152.90 (C-6), 153.41 (C-2), 154.02 (C-4), 167.49 (C]O). HRMS
(ESIþ) m/z calcd for C20H22F3N6O2 (M þ H)þ 435.1756, found
435.1748. Anal. Calcd for C20H21F3N6O2.0.5C6H14.0.28CH3COOC2H5:
C, 57.69; H, 6.07; N, 16.74. Found C, 57.80; H, 5.77; N, 16.34.
4.2. X-ray determination
Single crystal measurements on 28 were performed on an STOE
IPDS 2 two circles diffractometer equipped with graphite mono-
chromatorMoKaradiation. Structure was solved by direct methods
(SHELXS97) [48] and refined by least-squares procedures on Fsqd
(SHELXL97) [49]. The refinement was made with anisotropic
displacement factors for all non-hydrogen atoms. All hydrogen
atoms were calculated to their idealized positions and refined as
riding atoms. The geometric calculations were carried out with the
program Platon [50].
4.3. Biological evaluation
4.3.1. Cells and culture
The human primary liver cancer cell lines provided from ATCC
(Huh7, HepG2, Hep3B, PLC, SKHep1, Mahlavu and FOCUS) and
(Snu182 and Snu475) were grown in Dulbecco's Modified Eagle'sMedium (DMEM) (Invitrogen GIBCO) and RPMI-1640 (Invitrogen
GIBCO), respectively; with 10% fetalbovine serum (FBS) (Invitrogen
GIBCO), non essential amino acids, and 1% penicillin (biochrome)
and incubated in 37 C with 5% CO2.
The cell line passage numbers were not tracked and recorded,
due to the fact that drug-induced senescence is not a conclusion of
telomere-shortening as if it is known to trigger replicative
senescence.
Each cell line has its own splitting agenda according to its pro-
liferation rate. All the cell lines mentioned above are adherent cells
growing attached to the surface of cell culture dishes. To subculture
these cells, trypsin was used to bring them into cell suspension and
prior to trypsinization, the cells were washed twice with 1xPBS to
get rid of the swimming (i.e. dead) cells and the cell growth me-
dium, containing FBS. However, if the cells were incubatedwith test
compounds, positive controls or only-DMSO, the swimming cells
were collected and included to the cell lysates which were further
analysed in order to assess the cytotoxicity of the test compounds
accurately.
The DMSO (Sigma) was used as solvent for the compounds. The
concentration of DMSO was always less than 1% in the cell culture
medium. Drugs (Camptothecin, 5-FU, Doxorubicin and Staur-
osporine) used as positive control were from Calbiochem.
4.3.2. Sulforhodamine B (SRB) assay for cytotoxicity screening
All cancer cells were inoculated (2000 cell/well to 10,000 cell/
well in 200 mL/well) to 96-well plates at 37 C in 5% CO2. Next day,
the media of the wells were refreshed and the molecules to be
testedwhich were already dissolved in DMSOwere applied directly
to the first wells in calculated volumes to obtain the decided
highest drug concentration. Cancer cells were also treated with
DMSO-only simultaneously to avoid its solitary effect. Following
the drug treatment, plates were incubated again at 37 C in a hu-
midified 5% CO2 and 95% air incubator for different time periods. At
the 24th, 48th and 72nd hour of drug treatment, cancer cells were
fixed with ice-cold TCA (50 mL/well) and kept at þ4 C in dark for
exactly 1 h. TCA fixation was terminated by washing the wells with
ddH2O for 5 times. Air-dried plates were stained with 0.4% sul-
phorhodamine B (SRB) dissolved in 1% acetic acid solution for
10 min in dark and at room temperature. The plates which were
quickly rinsed with 1% acetic acid solution to get rid of the unbound
SRB dyewere left to air dry. The protein-bound and dried SRB dye is
then solubilized with 10 mM Tris-Base solution (200 mL/well) and
homogenized on a shaker for 5e10 min. The absorbance values
were obtained at 515 nm by means of a microplate reader and used
to calculate the cell death percentage as follows: % inhibition ¼ 100
(1ODdrug/ODDMSO). The IC50 values were determined from the
doseeresponse curves plotted as percent growth inhibition vs. drug
concentration.
4.3.3. Nuclear staining with Hoechst 33258
Cancer cells, inoculated onto coverslips placed in 6-well plates,
were treated on the next day with the decided concentrations of
compounds to be tested and their DMSO-only and left to incubation
at 37 C in 5% CO2. At the end of determined incubation period, the
wells were washed with ice-cold 1xPBS and fixed with 3% form-
aldehyde before stained 5 min with Hoechst 33258 working solu-
tion at room temperature. Thewells were destainedwith ddH2O for
10 min. The nuclear morphology was examined under a fluorescent
microscope.
4.3.4. Western blot analysis
Proteins were generated from Mahlavu and FOCUS cells treated
with compound 17, 28, 36 and STS. Cells treated with these com-
pounds and only DMSO were collected entirely; not only attached
Z. Demir et al. / European Journal of Medicinal Chemistry 89 (2015) 701e720 719cells but also swimming cells were taken. Total homogenates from
cells were resuspended in 50 mM TriseHCl pH 7.4, 1 mM EDTA,
1 mM EGTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS with protease
inhibitor cocktail and phosphatase inhibitors. Novex®NuPAGE®Bis-
Tris Electrophoresis system was used according to the manufac-
turer's protocol for all westernblotting analysis. Eventually, the
expression of the protein levels was visualized via ECL þ kit that is
used according to the manufacturer's recommendations. Actin and
calnexin proteins were used for equal loading control. Bcl-2, Cy-
tochrome-c and PARP-1 antibodies were purchased from Santa
Cruz Biotechnology.
4.3.5. Kinase assay
The calculated amount of cell lysate was mixed with kinase
reaction buffer (40 mM TriseHCl pH7.6, 20 mM MgCl2, 0.1 mg/ml
BSA) to give a final volume of 40 mL in a white, 96-well, poly-
propylene assay plate. Then 20 mL Lonza reagent (ATP detection
reagent) was added. After 10 min dark incubation at room tem-
perature, the luminescence was detected through a luminometer.
This assay exploits intrinsic ATPase activity of a kinase that results
in the phosphorylation of the target substrate in expense of the
conversion of ATP to ADP. Hypothetically consumed ATP is evalu-
ated by measuring the bioluminescence generated by the remain-
ing ATP upon the addition of the ATP detection reagent which is
utilizing the enzyme luciferase, generating light from ATP and
luciferin. The cell lysates we have used in this assay were previously
incubated with three purine analogues, a multi-kinase inhibitor,
STS (as a positive control), and only-DMSO for 24 h. Since we have
not added any exogenous ATP and the commercial kit also do not
contain, the intensity of the stable light signal emitted is linearly
proportional to the concentration of ATP remained in the cell ly-
sates after 24 h drug treatment. High levels of bioluminescence
depict the blockage of ATP consumption; in other words, increase
in the light intensity can be considered as an indirect evidence of
the ATPase inhibition, hence a kinase inhibitor.
4.3.6. Real-time cell electronic sensing (RT-CES) method for
cytotoxicity profiling
This technology utilizes the microelectronic plates (E-plates, 96-
well) with wells covered with gold microelectrodes at the bottom.
An electric field forms between these electrodes after a low voltage
application. Addition of adherent cancer cells causes changes in
electrical impedance (Z) which is proportional to cell numbers.
These changes, displayed as Cell Index (CI) values, reveal the
adhesion status of the cells in the electrode-surrounded well; in
other words cell growth can be traced by increasing CI values due to
the lack of swimming, detached cells. Proliferation of primary liver
cancer cell lines was monitored in real-time cell electronic sensing
RT-CES (xCELLigence-Roche Applied Science), and the CI values
were measured every 30 min for at least 120 h.Huh7, HepG2, and
Mahlavu cells were inoculated (2000 cell/well in 200 ml) in the E-96
plate on the xCELLigence station in 5% CO2 at 37 C. The CI values
were recorded at every 30 min. Next day, 150 ml medium from each
well was replaced with 100 ml fresh medium and compound 36
applied to each well in indicated concentrations. The drug-treated
E-96 plate was again placed on the RT-CES station. The CI values
were recorded at every 30 min to monitor real time drug response.
DMSO-only and medium-only wells were also included to avoid
their solitary effects on cancer cells.
4.3.7. Senescence associated-b-gal assay and BrdU proliferation co-
staining
Huh7 cells (5000 cell) inoculated to 2 identical 6-well plates on
coverslips. Next day, the compound 36 and doxorubicin at indicated
concentrations and their corresponding DMSO-only controls wereapplied to the plates. At the day 3 and the day 6, Senescence
Associated-b-gal (SA-b-gal) assay and BrdU co-staining were
established.24 h prior to the assays mediums, (both compound 36
and its corresponding DMSO-only containing) were refreshed. For
one of the 6-well plates, the freshly prepared mediums were also
containing 30 mM BrdU (5-bromo-2-deoxyuridine). SA-b-gal and
BrdU co-staining were done as described previously [51,52].
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